|
Median age, years (range)
|
66 (44.3–83.3)
|
|
Median follow-up, months (range)
|
47.3 (1–76.9)
|
|
Gender
|
|
Male
|
35
|
76.1
|
|
Female
|
11
|
23.9
|
|
Histology
|
|
Squamous
|
22
|
47.8
|
|
Non-squamous
|
24
|
52.2
|
|
Performans Status - ECOGa
|
|
0
|
27
|
71.1
|
|
1
|
11
|
28.9
|
|
Missing
|
8
| |
|
Location of relapse
|
|
Central
|
24
|
52.2
|
|
Peripheral
|
22
|
47.8
|
|
In-field relapse
|
|
Yes
|
29
|
63
|
|
No
|
17
|
37
|
|
Primary stage (at first irradiation)
|
|
IIIA
|
21
|
45.7
|
|
IIIB
|
25
|
54.3
|
|
Concurrent chemotherapy at first irradiation
|
|
Yes
|
35
|
76.1
|
|
No
|
11
|
23.9
|
|
Surgery immediately after the first irradiation
|
|
Yes
|
11
|
23.9
|
|
No
|
35
|
76.1
|
|
First irradiation
|
|
Median total dose
|
66 Gy (44–70)
| |
|
Median dose per fraction
|
2 Gy (1.8–2.3)
| |
|
Total dose < 60 Gy
|
7 patients
| |
|
Median BED dose
|
79.2 Gy (39–90)
| |
|
Concomitant chemotherapy (first irradiation)
| |
|
Cisplatin - Docetaxel
|
17
|
54.8
|
|
Carboplatin – Paclitaxel
|
3
|
9.7
|
|
Cisplatin – Navelbine
|
3
|
9.7
|
|
Carboplatin – Etoposide
|
2
|
6.5
|
|
Carboplatin - Docetaxel
|
2
|
6.5
|
|
Cisplatin – Paclitaxel
|
1
|
3.2
|
|
Cisplatin – Etoposide
|
1
|
3.2
|
|
Carboplatin – Gemcitabine
|
1
|
3.2
|
|
Carboplatin - Navelbine
|
1
|
3.2
|
|
Unknown
|
4
| |
|
Reirradiation
| |
|
Median delay between irradiations
|
22.6 (6.2–101.5)
| |
|
Median tumor size in mm
|
33 (10–60)
| |
|
Median GTV in mL
|
13.2 mL (1.1–79.1)
| |
|
Median duration of treatment in days
|
5 (3–12)
| |
|
Median total physical prescribed dose in Gy
|
60 (40–75)
| |
|
Median prescribed dose per fraction in Gy
|
16 (10–20)
| |
|
Median number of sessions
|
4 (3–5)
| |
|
Median BEDisocenter in Gy
|
132 (72–187.5)
| |
|
Median BED in Gy
|
50.2 (6.7–189.1)
| |
|
Isodose of prescription in %
|
80 (70–83)
| |
|
Median GTV coverage in %
|
95.6 (43.8–100)
|
|
Median PTV coverage in %
|
90.2 (34.8–100)
|
|
Adjuvant chemotherapy after reirradiation
|
|
Yesa
|
10
|
21.7
|
|
No
|
36
|
78.3
|
